首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

2065200

家庭輸液治療市場預測至2034年－按產品、給藥途徑、治療方法、最終用戶和地區分類的全球分析

Home Infusion Therapy Market Forecasts to 2034 - Global Analysis By Product (Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors, and Consumables & Accessories), Route of Administration, Therapy, End User and By Geography

出版日期: 2026年06月11日 | 出版商:

Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，預計到 2026 年，全球家庭輸液治療市場規模將達到 284 億美元，到 2034 年將達到 589 億美元，預測期內複合年成長率為 9.6%。

居家輸液治療是一種臨床實踐，允許患者在訓練有素的醫護人員的監督下，在家中舒適地接受靜脈注射和其他注射藥物。治療範圍廣泛，包括抗生素、化療、腸外營養、疼痛管理、免疫球蛋白療法和特殊生物製藥。先進的輸液幫浦、輸液裝置和監測技術確保在傳統醫院環境之外安全、準確地輸送藥物。這種模式有助於縮短住院時間、降低整體醫療成本、提高病患的生活品質，並支持以價值為導向的醫療服務模式。

慢性病盛行率上升和人口老化

癌症、糖尿病、自體免疫疾病和感染疾病等慢性疾病在全球日益加重，從根本上改變了醫療服務模式。隨著人口老化，越來越多的患者需要長期藥物治療，而按照傳統模式，這通常意味著頻繁的住院。居家輸液治療透過實現居家持續治療，減少住院和再入院次數，有效應對了這項挑戰。由於居家輸液治療在顯著降低住院成本的同時，也能維持良好的臨床療效，因此保險公司和醫療系統都在積極推廣應用。攜帶式輸液設備、遠端醫療監測和藥劑師管理方案的進步，進一步保障了居家照護的安全。

複雜的報銷環境和不足的保險覆蓋。

儘管家庭輸液治療具有臨床優勢，但其市場仍面臨公共和私人支付方報銷政策不一致等持續性挑戰。特定治療方法和藥物的適用標準差異顯著，這不僅增加了醫療服務提供者的行政管理難度，也為患者帶來了經濟上的不確定性。缺乏統一的計費代碼以及頻繁的預先核准要求，導致治療啟動延遲，並降低了醫療服務提供者的利潤率。小規模輸液藥局和獨立醫療服務提供者尤其脆弱，他們與支付方的議價能力有限，這進一步加劇了其收入週期的困難。

專業生物製藥的擴張和生物相似藥的推廣

生物製藥在類風濕性關節炎、多發性硬化症、克隆氏症和罕見遺傳性疾病等疾病治療領域的快速發展，催生了對先進家庭輸液服務的巨大需求。隨著生物相似藥進入這些治療領域，成本降低可望擴大患者用藥範圍並增加治療次數。專業的輸液服務提供者正投資於低溫運輸物流、病患教育計畫和臨床協調平台，以搶佔這個不斷成長的市場。藥品福利管理公司、生技公司和居家醫療提供者之間的策略合作，正在開拓進一步的成長潛力。

藥品短缺和供應鏈脆弱性

居家輸液治療產業仍極易受到藥品供應鏈中斷的影響，尤其是高需求量的靜脈注射藥物和關鍵電解質。生產中斷、原料短缺或地緣政治貿易中斷導致的藥品短缺會延誤病患治療，迫使醫療機構尋求成本高昂的替代採購管道。對藥房的監管進一步增加了營運風險。雖然建立穩健且多元化的供應商網路並維持安全庫存至關重要，但這會增加成本壓力，小規模醫療機構可能難以承受。

新型冠狀病毒（COVID-19）的影響：

新冠疫情加速了居家照護的普及，因為醫院優先治療重症新冠患者，導致非緊急治療資源有限。疫情期間，遠距遠端醫療、遠端患者監護以及保險公司更靈活的政策，為居家輸液治療提供了結構性推動。疫情過後，患者和臨床醫師仍然強烈傾向居家照護。然而，供應鏈中斷暴露了藥品採購和靜脈輸液供應的系統性脆弱性。整體而言，疫情促使監理改革加速了保險覆蓋範圍的擴大和市場的成熟。

在預測期內，輸液幫浦細分市場預計將佔據最大的市場佔有率。

由於輸液幫浦在精準、可程式設計的藥物傳遞方面發揮著至關重要的作用，因此它在家庭輸液治療市場中佔據最大佔有率。彈性體幫浦和攜帶式幫浦因其結構緊湊、操作簡便且無需電源，廣泛用於門診和家庭治療。諸如配備劑量誤差減少軟體和無線連接功能的智慧幫浦等技術進步，正在提升病患安全性和遠端臨床監測能力。腫瘤治療、抗感染疾病和營養治療需求的不斷成長，也直接推動了輸液幫浦的使用。

預計在預測期內，靜脈注射（IV）給藥途徑細分市場將錄得最高的複合年成長率。

由於靜脈注射途徑具有更高的生物利用度、起效迅速以及適用於包括抗生素、生物製藥和化療藥物在內的多種藥物，預計在預測期內，靜脈給藥途徑的複合年成長率將最高。對於需要精確劑量和即時全身作用的疾病，靜脈治療仍是黃金標準。隨著周邊和中心靜脈通路裝置的改進，靜脈注射生物製藥在家庭環境中的仿單標示外和適應症外使用正在增加，這促進了基於靜脈注射輸注的家庭輸液方案的加速推廣。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。北美在全球家庭輸液治療市場中佔據最大佔有率，這得益於其成熟的醫療保健基礎設施、完善的聯邦醫療保險和醫療補助報銷機制，以及廣泛的專業輸液藥房網路。美國佔據了該地區銷售額的大部分，這主要得益於慢性病的高發生率、患者對居家照護的強烈偏好以及先進輸液泵技術的廣泛應用。聯邦醫療保險和醫療補助服務中心 (CMS) 對居家醫療福利的監管支持進一步鞏固了北美的市場領導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。受中國、印度、日本和韓國醫療基礎設施快速擴張的推動，亞太地區預計將在預測期內實現最高的複合年成長率。人們對居家照護模式的日益了解、政府推廣社區醫療保健的舉措以及有能力負擔私人保險的中產階級不斷壯大，共同推動了市場需求。隨著專科藥房網路的擴張、生物製藥處方量的增加以及對利用遠端醫療的家庭監測平台的投資，亞太地區預計將成為2034年成長最快的區域市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

企業概況
- 對其他市場參與者（最多 3 家公司）進行全面分析
- 對主要公司進行SWOT分析（最多3家公司）
區域細分
- 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
競爭性標竿分析
- 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 比利時
- 瑞典
- 瑞士
- 波蘭
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 泰國
- 馬來西亞
- 新加坡
- 越南
- 其他亞太國家
南美洲
- 巴西
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 其他南美國家
世界其他地區（RoW）
- 中東
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 卡達
  - 以色列
  - 其他中東國家
- 非洲
  - 南非
  - 埃及
  - 摩洛哥
  - 其他非洲國家

第10章戰略市場資訊

工業價值網路和供應鏈評估
空白區域和機會地圖
產品演進與市場生命週期分析
通路、經銷商和打入市場策略的評估

第11章產業趨勢與策略舉措

併購
夥伴關係、聯盟和合資企業
新產品發布和認證
擴大生產能力和投資
其他策略舉措

第12章：公司簡介

Baxter International Inc.
B. Braun SE
Becton, Dickinson and Company
Fresenius Kabi AG
ICU Medical, Inc.
Terumo Corporation
Option Care Health, Inc.
CareCentrix, Inc.
Moog Inc.
JMS Co., Ltd.
Nipro Corporation
Eitan Medical Ltd.
Caesarea Medical Electronics Ltd.
Optum, Inc.
Amedisys, Inc.

簡介目錄圖表

Product Code: SMRC36760

According to Stratistics MRC, the Global Home Infusion Therapy Market is accounted for $28.4 billion in 2026 and is expected to reach $58.9 billion by 2034, growing at a CAGR of 9.6% during the forecast period. Home Infusion Therapy is a clinical practice that enables patients to receive intravenous or other injectable medications in the comfort of their homes, managed by trained healthcare professionals. It covers a broad range of treatments including antibiotics, chemotherapy, parenteral nutrition, pain management, immunoglobulin therapy, and specialty biologics. Advanced infusion pumps, IV sets, and monitoring technologies ensure safe and accurate drug delivery outside traditional hospital settings. This model reduces inpatient stays, lowers overall healthcare expenditure, improves patient quality of life, and supports value-based care initiatives.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases and aging population

The expanding global burden of chronic illnesses such as cancer, diabetes, autoimmune disorders, and infectious diseases is fundamentally reshaping care delivery models. An aging demographic increasingly requires long-term medication regimens that demand frequent hospital visits under traditional frameworks. Home infusion therapy resolves this challenge by enabling continuous treatment at home, reducing hospitalizations and readmissions. Payers and health systems are incentivizing its adoption as it substantially cuts inpatient costs while maintaining clinical outcomes. Advances in portable infusion devices, telehealth monitoring, and pharmacist-managed protocols further support safe home-based care.

Restraint:

Complex reimbursement landscape and insurance coverage gaps

Despite its clinical advantages, the home infusion therapy market faces persistent challenges related to inconsistent reimbursement policies across government and private payers. Coverage criteria for specific therapies and medications vary widely, creating administrative complexity for providers and financial uncertainty for patients. The lack of a unified billing code framework and frequent prior authorization requirements slow therapy initiation and reduce provider margins. Smaller infusion pharmacies and independent operators are particularly vulnerable, as limited negotiating power with payers compounds revenue cycle difficulties.

Opportunity:

Expansion of specialty biologics and biosimilar adoption

The rapid growth of biologics for conditions such as rheumatoid arthritis, multiple sclerosis, Crohn's disease, and rare genetic disorders has created significant demand for sophisticated home infusion services. As biosimilars enter these therapeutic categories, cost reductions are expected to broaden patient access and increase therapy volumes. Specialty infusion providers are investing in cold-chain logistics, patient education programs, and clinical coordination platforms to capture this expanding market. Strategic alliances between pharmacy benefit managers, biotech companies, and home health agencies are further unlocking growth potential.

Threat:

Drug shortages and supply chain vulnerabilities

The home infusion therapy sector remains susceptible to pharmaceutical supply chain disruptions, particularly for high-demand IV medications and critical electrolytes. Drug shortages triggered by manufacturing shutdowns, raw material scarcity, or geopolitical trade disruptions can delay patient therapies and force providers into costly alternative sourcing. Regulatory scrutiny over compounding pharmacies adds another layer of operational risk. Building resilient, diversified supplier networks and maintaining safety stock inventories are essential strategies, but they add cost pressures that smaller providers may struggle to absorb.

Covid-19 Impact:

The COVID-19 pandemic accelerated the shift toward home-based care as hospitals prioritized capacity for acute COVID-19 patients, limiting access for non-emergency therapies. Telehealth integration, remote patient monitoring, and expanded insurer flexibilities during the pandemic gave home infusion therapy a structural boost. Post-pandemic, patients and clinicians retained strong preferences for home-based care delivery. However, supply chain disruptions exposed systemic vulnerabilities in drug procurement and IV fluid availability. Overall, the pandemic catalyzed regulatory changes that expanded coverage and accelerated market maturation.

The Infusion Pumps segment is expected to be the largest during the forecast period

The infusion pumps segment commands the largest share of the home infusion therapy market, underpinned by their indispensable role in accurate, programmable drug delivery. Elastomeric and ambulatory pumps are widely preferred for outpatient and home use due to their compact design, ease of operation, and eliminating the need for electrical power sources. Technological advancements including smart pumps with dose-error reduction software and wireless connectivity are enhancing patient safety and clinical oversight from remote locations. Rising demand for oncology, anti-infective, and nutritional therapies directly fuels pump utilization.

The Intravenous (IV) Route segment is expected to have the highest CAGR during the forecast period

The intravenous route of administration is projected to register the highest CAGR over the forecast period, driven by its superior bioavailability, rapid onset of action, and suitability for a diverse range of medications including antibiotics, biologics, and chemotherapy agents. IV therapy remains the gold standard for conditions requiring precise dosing and immediate systemic effect. The growing off-label and on-label use of IV biologics in home settings, supported by improved peripheral and central venous access devices, is contributing to accelerated adoption of IV-based home infusion protocols.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, North America retains the largest share of the global home infusion therapy market, backed by a mature healthcare infrastructure, well-established reimbursement frameworks under Medicare and Medicaid, and widespread availability of specialty infusion pharmacy networks. The United States accounts for the dominant portion of regional revenues, driven by high chronic disease prevalence, strong patient preference for home-based care, and robust adoption of advanced infusion pump technologies. Regulatory support from the Centers for Medicare and Medicaid Services for home health benefits further reinforces North America's market leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Asia Pacific is anticipated to register the highest CAGR over the forecast period, propelled by rapid healthcare infrastructure expansion across China, India, Japan, and South Korea. Rising awareness of home-based care models, government initiatives promoting community healthcare, and growing middle-class populations with access to private insurance are collectively driving demand. The expansion of specialty pharmacy networks, increasing biologic prescriptions, and investments in telehealth-enabled home monitoring platforms position Asia Pacific as the fastest-growing regional market through 2034.

Key players in the market

Some of the key players in Global Home Infusion Therapy Market include Baxter International Inc., B. Braun SE, Becton, Dickinson and Company, Fresenius Kabi AG, ICU Medical Inc., Terumo Corporation, Option Care Health Inc., CareCentrix Inc., Moog Inc., JMS Co. Ltd., Nipro Corporation, Eitan Medical Ltd., Caesarea Medical Electronics Ltd., Optum Inc., and Amedisys Inc.

Key Developments:

In March 2026, Baxter International announced an expanded strategic partnership with a leading telehealth provider to integrate real-time infusion monitoring capabilities into its connected pump platform, enabling clinicians to remotely oversee home-based therapy sessions and receive automated alerts for pump anomalies across multiple patient settings.

In February 2026, Option Care Health completed the acquisition of a regional specialty infusion pharmacy operator across three southeastern US states, expanding its home infusion footprint and adding oncology and immunology therapy capabilities to its portfolio, with plans to integrate the acquired operations into its existing care management infrastructure by mid-2026.

Products Covered:

Infusion Pumps
Intravenous Sets
IV Cannulas
Needleless Connectors
Consumables & Accessories

Route of Administrations Covered:

Intravenous (IV)
Subcutaneous
Epidural
Intramuscular

Therapies Covered:

Anti-Infective Therapy
Endocrinology
Chemotherapy
Hydration Therapy
Enteral Nutrition
Blood Factor Therapy
Parenteral Nutrition
Specialty Pharmaceuticals
Pain Management
Immunoglobulin Therapy

End Users Covered:

Home Care Settings
Hospitals
Ambulatory Infusion Centers
Specialty Clinics
Long-Term Care Centers
Other End Users

Regions Covered:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
Rest of the World (RoW)
- Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
- Africa
South Africa
Egypt
Morocco
Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework

2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
- 2.4.1 Data Collection (Primary and Secondary)
- 2.4.2 Data Modeling and Estimation Techniques
- 2.4.3 Data Validation and Triangulation
- 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

4.1 Porter's Five Forces Analysis
- 4.1.1 Supplier Bargaining Power
- 4.1.2 Buyer Bargaining Power
- 4.1.3 Threat of Substitutes
- 4.1.4 Threat of New Entrants
- 4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global Home Infusion Therapy Market, By Product

5.1 Infusion Pumps
- 5.1.1 Elastomeric Pumps
- 5.1.2 Electromechanical Pumps
- 5.1.3 Gravity Pumps
- 5.1.4 Ambulatory Pumps
- 5.1.5 Syringe Pumps
5.2 Intravenous Sets
5.3 IV Cannulas
5.4 Needleless Connectors
5.5 Consumables & Accessories
- 5.5.1 Catheters
- 5.5.2 Tubing
- 5.5.3 Connectors
- 5.5.4 Dressing Kits

6 Global Home Infusion Therapy Market, By Route of Administration

6.1 Intravenous (IV)
6.2 Subcutaneous
6.3 Epidural
6.4 Intramuscular

7 Global Home Infusion Therapy Market, By Therapy

7.1 Anti-Infective Therapy
7.2 Endocrinology
7.3 Chemotherapy
7.4 Hydration Therapy
7.5 Enteral Nutrition
7.6 Blood Factor Therapy
7.7 Parenteral Nutrition
7.8 Specialty Pharmaceuticals
7.9 Pain Management
7.10 Immunoglobulin Therapy

8 Global Home Infusion Therapy Market, By End User

8.1 Home Care Settings
8.2 Hospitals
8.3 Ambulatory Infusion Centers
8.4 Specialty Clinics
8.5 Long-Term Care Centers
8.6 Other End Users

9 Global Home Infusion Therapy Market, By Geography

9.1 North America
- 9.1.1 United States
- 9.1.2 Canada
- 9.1.3 Mexico
9.2 Europe
- 9.2.1 United Kingdom
- 9.2.2 Germany
- 9.2.3 France
- 9.2.4 Italy
- 9.2.5 Spain
- 9.2.6 Netherlands
- 9.2.7 Belgium
- 9.2.8 Sweden
- 9.2.9 Switzerland
- 9.2.10 Poland
- 9.2.11 Rest of Europe
9.3 Asia Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 South Korea
- 9.3.5 Australia
- 9.3.6 Indonesia
- 9.3.7 Thailand
- 9.3.8 Malaysia
- 9.3.9 Singapore
- 9.3.10 Vietnam
- 9.3.11 Rest of Asia Pacific
9.4 South America
- 9.4.1 Brazil
- 9.4.2 Argentina
- 9.4.3 Colombia
- 9.4.4 Chile
- 9.4.5 Peru
- 9.4.6 Rest of South America
9.5 Rest of the World (RoW)
- 9.5.1 Middle East
  - 9.5.1.1 Saudi Arabia
  - 9.5.1.2 United Arab Emirates
  - 9.5.1.3 Qatar
  - 9.5.1.4 Israel
  - 9.5.1.5 Rest of Middle East
- 9.5.2 Africa
  - 9.5.2.1 South Africa
  - 9.5.2.2 Egypt
  - 9.5.2.3 Morocco
  - 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

10.1 Industry Value Network and Supply Chain Assessment
10.2 White-Space and Opportunity Mapping
10.3 Product Evolution and Market Life Cycle Analysis
10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

11.1 Mergers and Acquisitions
11.2 Partnerships, Alliances, and Joint Ventures
11.3 New Product Launches and Certifications
11.4 Capacity Expansion and Investments
11.5 Other Strategic Initiatives

12 Company Profiles

12.1 Baxter International Inc.
12.2 B. Braun SE
12.3 Becton, Dickinson and Company
12.4 Fresenius Kabi AG
12.5 ICU Medical, Inc.
12.6 Terumo Corporation
12.7 Option Care Health, Inc.
12.8 CareCentrix, Inc.
12.9 Moog Inc.
12.10 JMS Co., Ltd.
12.11 Nipro Corporation
12.12 Eitan Medical Ltd.
12.13 Caesarea Medical Electronics Ltd.
12.14 Optum, Inc.
12.15 Amedisys, Inc.

簡介目錄圖表

List of Tables

Table 1 Global Home Infusion Therapy Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Home Infusion Therapy Market Outlook, By Product (2023-2034) ($MN)
Table 3 Global Home Infusion Therapy Market Outlook, By Infusion Pumps (2023-2034) ($MN)
Table 4 Global Home Infusion Therapy Market Outlook, By Elastomeric Pumps (2023-2034) ($MN)
Table 5 Global Home Infusion Therapy Market Outlook, By Electromechanical Pumps (2023-2034) ($MN)
Table 6 Global Home Infusion Therapy Market Outlook, By Gravity Pumps (2023-2034) ($MN)
Table 7 Global Home Infusion Therapy Market Outlook, By Ambulatory Pumps (2023-2034) ($MN)
Table 8 Global Home Infusion Therapy Market Outlook, By Syringe Pumps (2023-2034) ($MN)
Table 9 Global Home Infusion Therapy Market Outlook, By Intravenous Sets (2023-2034) ($MN)
Table 10 Global Home Infusion Therapy Market Outlook, By IV Cannulas (2023-2034) ($MN)
Table 11 Global Home Infusion Therapy Market Outlook, By Needleless Connectors (2023-2034) ($MN)
Table 12 Global Home Infusion Therapy Market Outlook, By Consumables & Accessories (2023-2034) ($MN)
Table 13 Global Home Infusion Therapy Market Outlook, By Catheters (2023-2034) ($MN)
Table 14 Global Home Infusion Therapy Market Outlook, By Tubing (2023-2034) ($MN)
Table 15 Global Home Infusion Therapy Market Outlook, By Connectors (2023-2034) ($MN)
Table 16 Global Home Infusion Therapy Market Outlook, By Dressing Kits (2023-2034) ($MN)
Table 17 Global Home Infusion Therapy Market Outlook, By Route of Administration (2023-2034) ($MN)
Table 18 Global Home Infusion Therapy Market Outlook, By Intravenous (IV) (2023-2034) ($MN)
Table 19 Global Home Infusion Therapy Market Outlook, By Subcutaneous (2023-2034) ($MN)
Table 20 Global Home Infusion Therapy Market Outlook, By Epidural (2023-2034) ($MN)
Table 21 Global Home Infusion Therapy Market Outlook, By Intramuscular (2023-2034) ($MN)
Table 22 Global Home Infusion Therapy Market Outlook, By Therapy (2023-2034) ($MN)
Table 23 Global Home Infusion Therapy Market Outlook, By Anti-Infective Therapy (2023-2034) ($MN)
Table 24 Global Home Infusion Therapy Market Outlook, By Endocrinology (2023-2034) ($MN)
Table 25 Global Home Infusion Therapy Market Outlook, By Chemotherapy (2023-2034) ($MN)
Table 26 Global Home Infusion Therapy Market Outlook, By Hydration Therapy (2023-2034) ($MN)
Table 27 Global Home Infusion Therapy Market Outlook, By Enteral Nutrition (2023-2034) ($MN)
Table 28 Global Home Infusion Therapy Market Outlook, By Blood Factor Therapy (2023-2034) ($MN)
Table 29 Global Home Infusion Therapy Market Outlook, By Parenteral Nutrition (2023-2034) ($MN)
Table 30 Global Home Infusion Therapy Market Outlook, By Specialty Pharmaceuticals (2023-2034) ($MN)
Table 31 Global Home Infusion Therapy Market Outlook, By Pain Management (2023-2034) ($MN)
Table 32 Global Home Infusion Therapy Market Outlook, By Immunoglobulin Therapy (2023-2034) ($MN)
Table 33 Global Home Infusion Therapy Market Outlook, By End User (2023-2034) ($MN)
Table 34 Global Home Infusion Therapy Market Outlook, By Home Care Settings (2023-2034) ($MN)
Table 35 Global Home Infusion Therapy Market Outlook, By Hospitals (2023-2034) ($MN)
Table 36 Global Home Infusion Therapy Market Outlook, By Ambulatory Infusion Centers (2023-2034) ($MN)
Table 37 Global Home Infusion Therapy Market Outlook, By Specialty Clinics (2023-2034) ($MN)
Table 38 Global Home Infusion Therapy Market Outlook, By Long-Term Care Centers (2023-2034) ($MN)
Table 39 Global Home Infusion Therapy Market Outlook, By Other End Users (2023-2034) ($MN)